Friday - April 4, 2025
Zealand and Roche Form Largest Single Asset Partnership Deal Worth up to $5.3 billion to Co-Develop and Co-Commercialize Petrelintide Monotherapy and Potential Combination Products in the U.S. and Europe as Therapy for Obesity
March 13, 2025
BOSTON, Massachusetts, March 13 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:

* * *

Zealand and Roche Form Largest Single Asset Partnership Deal Worth up to $5.3 billion to Co-Develop and Co-Commercialize Petrelintide Monotherapy and Potential Combination Products in the U.S. and Europe as Therapy for Obesity

A multijurisdictional Life Sciences team advised Zealand Pharma ("Zealand") in its collaboration with . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products